H. pylori infection impairs the efficacy of anti-PD-1/CTLA4 immunotherapies or anticancer vaccines, and a lack of efficient targets impedes the treatment of H. pylori infection-associated GC (Oster et al., 2022). The gene discussed is CTLA4; the disease is gastric cancer.